Global Custom Market Research Reports Provider Company

phone

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018

  • Published Date: 10 Jul 2018
  • Number of Pages: 193
  • Category: Pharmaceuticals
  • Country: Global
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle cant get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 13, 4, 1, 17 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct


Introduction 5
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 6
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 7
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 17
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 25
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 38
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 163
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 169
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 172
Appendix 187

List Of Tables

List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by DalCor Pharmaceuticals Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Livzon Pharmaceutical Group Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Orion Corporation, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Reven Pharmaceuticals Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by XyloCor Therapeutics Inc, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2018 (Contd..2), H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2018 (Contd..3), H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2018 (Contd..1), H2 2018
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H2 2018 (Contd..2), H2 2018

List Of Figures

List of Figures
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Acute Coronary Syndrome: Competitive Landscape to 2026 Acute coronary syndrome (ACS) refers to a spectrum of myocardial ischemic states caused by the disruption of atherosclerotic plaques in the coronary arteries. The

View Report

Percutaneous Coronary Intervention Global Clinical Trials Review, H1, 2018 GlobalDatas clinical trial report, Percutaneous Coronary Intervention Global Clinical Trials Review, H1, 2018 provides an overview of Percutaneous Coronary Intervention clinical trials

View Report

Occlusive Coronary Artery Disease Global Clinical Trials Review, H1, 2018 GlobalDatas clinical trial report, Occlusive Coronary Artery Disease Global Clinical Trials Review, H1, 2018 provides an overview of Occlusive Coronary Artery

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports